Paul Vigano Sells 3,000,000 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder Paul Vigano sold 3,000,000 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $8.01, for a total transaction of $24,030,000.00. Following the transaction, the insider directly owned 190,130 shares in the company, valued at approximately $1,522,941.30. This represents a 94.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Aveanna Healthcare Price Performance

Shares of NASDAQ:AVAH opened at $9.10 on Friday. The stock has a market cap of $1.98 billion, a PE ratio of 7.71, a PEG ratio of 0.94 and a beta of 1.89. The company’s fifty day moving average is $7.36 and its 200 day moving average is $7.57. Aveanna Healthcare Holdings Inc. has a 52 week low of $3.73 and a 52 week high of $10.32. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 5.35.

Aveanna Healthcare (NASDAQ:AVAH) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.05. Aveanna Healthcare had a net margin of 10.37% and a return on equity of 124.68%. The business had revenue of $647.91 million during the quarter, compared to the consensus estimate of $613.22 million. Aveanna Healthcare’s quarterly revenue was up 15.9% compared to the same quarter last year. Research analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.65 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on AVAH shares. Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $10.00 to $11.00 in a research note on Friday, May 15th. BMO Capital Markets reduced their price target on Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating on the stock in a research report on Friday, March 20th. Raymond James Financial raised Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 price target on the stock in a research note on Friday, March 20th. Truist Financial lifted their price target on Aveanna Healthcare from $8.00 to $9.00 and gave the stock a “hold” rating in a research note on Wednesday, May 20th. Finally, Barclays lowered their price objective on Aveanna Healthcare from $9.50 to $9.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.50.

Hedge Funds Weigh In On Aveanna Healthcare

A number of hedge funds have recently modified their holdings of the company. AQR Capital Management LLC raised its stake in shares of Aveanna Healthcare by 21.2% during the first quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock valued at $142,000 after acquiring an additional 4,602 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Aveanna Healthcare by 8.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock valued at $1,842,000 after purchasing an additional 25,974 shares during the period. Jane Street Group LLC increased its holdings in Aveanna Healthcare by 522.0% during the 1st quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock valued at $407,000 after purchasing an additional 63,010 shares during the period. Creative Planning increased its holdings in Aveanna Healthcare by 15.1% during the 2nd quarter. Creative Planning now owns 47,025 shares of the company’s stock valued at $246,000 after purchasing an additional 6,171 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Aveanna Healthcare by 65.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock valued at $828,000 after purchasing an additional 62,348 shares during the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.